Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02865460 · ClinicalTrials.gov registry record · Phase 3
Coenzyme Q10 Phase III Trial in Gulf War Illness
A Phase 3 study of Gulf War Illness and Chronic Fatigue, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT02865460 is a Phase 3 study of Gulf War Illness and Chronic Fatigue that has completed, run by VA Office of Research and Development. The registered enrollment target is 100 participants, below the 123-participant average among 14 other Gulf War Illness trials with a reported enrollment target (19% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02865460, a Phase 3 study of Gulf War Illness and Chronic Fatigue, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of this clinical trial is to determine if treatment with ubiquinol, a form of coenzyme Q10, improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (SF-36), with respect to physical functioning and symptoms. Secondary outcome measures include changes from baseline levels on GWI-associated biomarkers in peripheral blood and GWI-associated symptoms of chronic pain, fatigue, insomnia, activity level, and cognitive and mental functioning.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ubiquinol
Study Locations (4)
Florida
- Miami VA Healthcare System, Miami, FL - Miami
Massachusetts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston
Minnesota
- Minneapolis VA Health Care System, Minneapolis, MN - Minneapolis
New York
- James J. Peters VA Medical Center, Bronx, NY - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-07-24 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02865460
The ClinicalTrials.gov registry entry for NCT02865460 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 14 other Gulf War Illness trials with a reported enrollment target (19% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Gulf War Illness appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02865460 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02865460 about?
NCT02865460 is a clinical study titled "Coenzyme Q10 Phase III Trial in Gulf War Illness". The primary objective of this clinical trial is to determine if treatment with ubiquinol, a form of coenzyme Q10, improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-i...
What is the current status of trial NCT02865460?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2017-07-24. Estimated completion is 2020-12-31.
What conditions does trial NCT02865460 study?
This clinical trial studies the following conditions: Gulf War Illness, Chronic Fatigue, Ubiquinol, Coenzyme Q10.
What interventions are being tested in trial NCT02865460?
The interventions under investigation include: Placebo (DRUG), Ubiquinol (DRUG).
Who is sponsoring clinical trial NCT02865460?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02865460 being conducted?
This trial has 4 study locations across Florida, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gulf War Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Confirmation of Diet as a Treatment for Gulf War Illness
RECRUITING · Phase 3
-
NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH)
RECRUITING
-
Validating Gulf War Illness Blood Biomarkers
RECRUITING
-
Nicotinamide Riboside Clinical Trial for GWI
RECRUITING · NA
-
Ca-Mg Butyrate in GWI
RECRUITING · Phase 2
-
Mechanisms of Gulf War Illness
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.